Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes
- Vivtex is eligible to receive up to $2.1 billion and royalties from Novo Nordisk.
- The collaboration focuses on developing oral biologics for obesity and diabetes.
- Vivtex's platform enhances oral bioavailability of peptide and protein therapeutics.
- Novo Nordisk will handle global development, regulatory, and commercialization.
Partnership Overview
Novo Nordisk and Vivtex have announced a collaboration to develop next-generation oral biologic medicines targeting obesity, diabetes, and related comorbidities. This partnership will utilize Vivtex's proprietary technologies to enhance the bioavailability of peptide and protein therapeutics.
Financial Details
Under the agreement, Vivtex is eligible to receive up to $2.1 billion, including upfront payments, research funding, and milestone payments. Additionally, Vivtex will earn tiered royalties on the net sales of future products developed through this collaboration.
Technological Integration
The collaboration aims to overcome the challenge of oral delivery for biologic drug candidates, which are typically limited to injectable forms due to poor gastrointestinal absorption. Vivtex's platform combines gastrointestinal screening assays, drug-delivery technologies, and AI capabilities to optimize oral formulations.
Roles and Responsibilities
Vivtex will license select oral drug-delivery technologies to Novo Nordisk, which will lead the global development, regulatory activities, manufacturing, and commercialization of any resulting products. This partnership expands Vivtex's platform into metabolic diseases and supports Novo Nordisk's mission to deliver innovative medicines.
Source: Novo Nordisk